Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female healthy adult subjects willing to sign a patient information and consent form (PICF) and able to undergo protocol related procedures.~* Age: 18 to 55 years, inclusive.~* Body Mass Index (BMI): 18.5 to 32.0 kg/m2.~* No history or evidence of a clinically significant disorder, condition, or disease that, in the opinion of the investigator would pose a risk to subject safety.~* Resting supine systolic blood pressure of ≤150 mmHg and diastolic blood pressure of ≤90 mmHg. Other vital signs showing no clinically relevant deviations according to the investigator's judgment.~* 12-lead ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the investigator.~* Negative urine drug screen and negative alcohol breath test at screening and admission.~Exclusion Criteria~* Subjects will be excluded from the study if one or more of the following criterion are applicable:~* Evidence of clinically relevant pathology~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to agent(s) used in study.~* Known history of previous exposure to adalimumab or other anti TNF-alpha molecules.~* Subjects with a recent (within 6 months of dosing) infection requiring hospitalisation or intravenous antibiotic use.~* Subjects with a recent (within 4 weeks of dosing) infection requiring oral or systemic antibiotics.~* Subject with a history of recurrent or chronic infections.~* Subject has a positive test for tuberculosis (TB) during screening or a known history of active or latent TB, except documented and complete adequate treatment of TB.~* Having received live vaccines during the 4 weeks before screening or have the intention to receive vaccination during the study.~* Participation in a drug study within 60 days or 5 half-lives of the previous drug (if known), whichever is longer, prior to drug administration Note: Only the few inclusion/exclusion criteria are mentioned here. Subjects will be screened and randomized as per the full list of inclusion and exclusion criteria in the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- AVT02 100mg/mL (Type: EXPERIMENTAL): Biosimilar Adalimumab AVT02
- EU-Humira 100mg/mL (Type: ACTIVE_COMPARATOR): EU Approved Adalimumab originator Humira
- US-Humira 100mg/mL (Type: ACTIVE_COMPARATOR): US licensed Adalimumab originator Humira

Based on this trial design, predict the completion outcome and termination type (if applicable).